Food and Drug Administration said on Friday that Novo Nordisk’s weight loss and diabetes drugs vegovi and ozmpic deficiency are solved, a step that can limit the availability of cheap mixed versions of wildly popular drugs.
In a statement, the FDA stated that it confirmed the “product availability and manufacturing capacity” of the Novo Nordisk of these prescription drugs or is higher than the current and estimated demand. The agency warned that consumers and doctors may still experience “limited local supply disruption” as products are sent from pharmaceutical factories to distributors.
Danish drug manufacturer Novo Nordisk said it has invested $ 6.5 billion in the United States this year, operating 24/7, shipping Vagovi and Ozampic to wholesalers.
Pharmaceutical giants who bring attractive weight loss drugs to the market have fought with firms that sell less expensive versions created by compounding pharmacies.
The FDA compounding allows pharmacies to sell copies of drugs when drugs occur in low supply. But compounding pharmacies have to face stifer restrictions on solving the lack of drug.
Need a little rest? Play USA daily crossword puzzles today.
Companies have mixed drugs-mixing, mixing, mixing, mixing or changing and decreasing drugs, is called GLP-1 (Glucagon-like peptide-1) receptor agonist.
Hims and Hars, who launched a super bowl advertisement, avoiding its weight loss product offerings, marketing a mixed version of Semaglutide, a ingredient active ingredient in the ozemic and vegovi. After the FDA’s announcement, the shares of HIMS & Hers in the morning trading recorded a 17% decline.
The FDA stated that it will not take enforcement action against pharmacies or doctors who make mixed semaglutides due to the decrease before 22 April. The features that will not face enforcement action before 22 May, compounds, distributed or distributed facilities.
In December, the FDA announced that the weight loss of Ellie Lily and diabetes drug tirzepetides, sold under brand names, which was no longer in the lower supply. This meant that pharmacies had to close the tirzepatide “compounding, distribution or dispensing” on 18 February. Suppliers who produce drug batches and sell to others are to close the distribution by 19 March.
Compounding pharmacies are regulated by the state boards of the pharmacy and the source material is usually obtained from the factories registered with the FDA. However, the federal agency compounding does not verify the safety or effectiveness of pharmacies.
